Ivantis Revenue and Competitors
Estimated Revenue & Valuation
- Ivantis's estimated annual revenue is currently $21.1M per year.
- Ivantis received $25.0M in venture funding in January 2017.
- Ivantis's estimated revenue per employee is $251,000
- Ivantis's total funding is $132.4M.
- Ivantis has 84 Employees.
- Ivantis grew their employee count by -54% last year.
Ivantis Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Ivantis?
Ivantis, Inc. is a company dedicated to the development of new and innovative solutions for glaucoma. Current therapies for primary open angle glaucoma (POAG) include eye drops, laser therapy, and surgery. But each of these has its limitations. Glaucoma remains the leading cause of blindness worldwide, in need of better treatment alternatives. It is our goal to develop new and effective solutions for ophthalmology specialists and the 70 million people worldwide who are affected by this debilitating and sight-stealing disease.keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
Number of Employees
Employee Growth %
Key Players Glaukos Corporation, Ivantis, Allergan, Ellex The New York Irish Emgirant...
... Equinox, Ivantis, Sight Sciences, TearClear, ViaLase ... Elios Vision, Ellex, Glaukos, iSTAR, Ivantis, New World Medical, Nicox,...
IRVINE, Calif., Sept. 15, 2021 /PRNewswire/ -- Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, today announced that it has entered into an agreement with Glaukos Corpo ...
IRVINE, Calif., Nov. 17, 2020 /PRNewswire/ -- Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, announced today that the American Academy of Ophthalmology (AAO) has desig ...
There are four FDA-approved MIGS stents: the Glaukos's iStent and iStent inject, Allergan XEN gel stent, and Ivantis Hydrus. That number could ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|2013-02-04||$27.0M||B||Ascension Health Ventures||Article|
|2013-08-21||$5.0M||B||EDBI of Singapore||Article|
|2017-01-10||$25.0M||C||RA Capital Management||Article|